medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2014-19-24-27medsovet-800Research ArticleОБЩАЯ УРОЛОГИЯGENERAL UROLOGYПрименение альфа-блокаторов для устранения симптомов со стороны нижних мочевыводящих путей при доброкачественной гиперплазии простатыUse of alpha-blockers to relieve lower urinary tract symptoms in benign prostatic hyperplasiaКривобородовГ. Г.KrivoborodovGGnoemail@neicon.ruРоссийский национальный исследовательский медицинский университет им. Н.И. Пирогова, МоскваРоссияPirogov Russian National Research Medical University, MoscowRussian Federation2014301220140192427Copyright © Кривобородов Г.Г., 20142014Кривобородов Г.Г.Krivoborodov G.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/800

Симптомы со стороны нижних мочевыводящих путей (СНМП) довольно распространены, особенно среди мужчин пожилого возраста, и могут быть вызваны многими заболеваниями. Резкое снижение качества жизни приводит этих пациентов к урологам, заставляя врачей дифференцированно подходить к выявлению причин СНМП и выбору метода их лечения.

Lower urinary tract symptoms (LUTS), which are quite common especially in elderly men, may be caused by a number of diseases. A sharp decline in the quality of life forces patients to see an urologist who has to apply a differentiated approach in order to identify the cause of LUTS and choose the correct method of treatment.

симптомы со стороны нижних мочевыводящих путейдоброкачественная гиперплазия простатыальфа-блокаторыlower urinary tract symptomsbenign prostatic hyperplasiaalpha-blockersReferencesAbrams P, Cardozo L, Fall M et al. The standardization of terminology of lower urinary tract function: report from Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002, 21: 167-178.Abrams P, Cardozo L, Fall M et al. The standardization of terminology of lower urinary tract function: report from Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002, 21: 167-178.Berry SJ, Coffey DS, Walsh PC et al. The development of human benign prostatic hyperplasia with age. J. Urology. 1984 Sep., 132(3): 474-479.Berry SJ, Coffey DS, Walsh PC et al. The development of human benign prostatic hyperplasia with age. J. Urology. 1984 Sep., 132(3): 474-479.Chapple CR, Roehrborn CG. A shifted paradigm for the further understanding, evalution and treatment of lower urinary tract symptoms in men: focus on the bladder. Eur Urology. 2006 Apr; 49(4): 651-658.Chapple CR, Roehrborn CG. A shifted paradigm for the further understanding, evalution and treatment of lower urinary tract symptoms in men: focus on the bladder. Eur Urology. 2006 Apr; 49(4): 651-658.St hrer M, Blok B, Castro-Diaz D, Chartier-Kastler E et al. Eur. Urol. 2009 Jul, 56(1): 81-8.St hrer M, Blok B, Castro-Diaz D, Chartier-Kastler E et al. Eur. Urol. 2009 Jul, 56(1): 81-8.van Kerrebroeck P, Chapple C, Drogendijk T et al. Combination therapy with Solifenacin and Tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial. European Urology. 2013, 5230: 2-10.van Kerrebroeck P, Chapple C, Drogendijk T et al. Combination therapy with Solifenacin and Tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial. European Urology. 2013, 5230: 2-10.Roehrborn CG, Siami P, Barkin J et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urology. 2010 Jan, 57(1): 123-131.Roehrborn CG, Siami P, Barkin J et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urology. 2010 Jan, 57(1): 123-131.EAU BPH guidelines. Madersbacher S et al. Eur Urol, 2004, 46: 547-554.EAU BPH guidelines. Madersbacher S et al. Eur Urol, 2004, 46: 547-554.Oelke M, Bachmann A, Descazeaud A et al. EAU guidelines on the management of male lower urinary tract symptoms, including benign prostatic obstruction. EAU guidelines 2013.Oelke M, Bachmann A, Descazeaud A et al. EAU guidelines on the management of male lower urinary tract symptoms, including benign prostatic obstruction. EAU guidelines 2013.AUA guidelines 2013.AUA guidelines 2013.Djavan B, Chapple C, Milani S et al. State of the art on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urology. 2004, Dec; 64(6): 1081-1088.Djavan B, Chapple C, Milani S et al. State of the art on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urology. 2004, Dec; 64(6): 1081-1088.McConnell JD, Roehrborn CG, Bautista O et al. The long-term effect of doxazosin, finasteride and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003 Dec, 349(25): 3287-2398.McConnell JD, Roehrborn CG, Bautista O et al. The long-term effect of doxazosin, finasteride and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003 Dec, 349(25): 3287-2398.Nickel JC, Sander S, Moon TD. A meta-analysis of the vascular-related safety profile and efficacy of a-adrenergic blockers for symptoms related to benign prostatic hyperplasia. Int J Clin Pract. 2008 Oct, 62(10): 1547-1549.Nickel JC, Sander S, Moon TD. A meta-analysis of the vascular-related safety profile and efficacy of a-adrenergic blockers for symptoms related to benign prostatic hyperplasia. Int J Clin Pract. 2008 Oct, 62(10): 1547-1549.Abrams P, Kaplan S, De Koning Gans HJ et al. Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. J. Urology. 2006 Mar, 175(5): 999-1004.Abrams P, Kaplan S, De Koning Gans HJ et al. Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. J. Urology. 2006 Mar, 175(5): 999-1004.Herschorn S, Jones JS, Oelke M et al. Efficacy and tolerability of fesoterodine in men with overactive bladder: a pooled analysis of 2 phase 3 studies. Urology. 2010 May, 75(5): 1149-1155.Herschorn S, Jones JS, Oelke M et al. Efficacy and tolerability of fesoterodine in men with overactive bladder: a pooled analysis of 2 phase 3 studies. Urology. 2010 May, 75(5): 1149-1155.

The authors declare that there are no conflicts of interest present.